SeouLinBioscienceCO

서린바이오 · 038070

Industrials Trading & Distribution · KOSDAQ

Small-cap

Market cap US$36.1M (₩49.8B)

Overview

SeouLinBioscience supplies the reagents, instruments, and consumables that biotech and pharmaceutical companies need to research, develop, and manufacture biological medicines, including cell therapies, gene therapies, antibody drugs, vaccines, and biosimilars.

Its customers range from basic life-science research labs to biopharmaceutical developers at every stage from early research through clinical trials and commercial production. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the overwhelming majority of its revenue from this bio-industry supply business, with smaller operations in hygiene and sterilisation solutions, AI-assisted bio-analysis services, and medical aesthetics run through a subsidiary.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$55.9M

▲ +2.2% YoY

Operating profit · FY2025

US$501.2K

▼ −27.4% YoY

Net income · FY2025

US$415.8K

▼ −81.7% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$64.9M(₩89.6B)	US$54.6M(₩75.4B)	US$55.9M(₩77.1B)
Operating profit	US$1.8M(₩2.5B)	US$690.3K(₩952.7M)	US$501.2K(₩691.6M)
Net income	−US$1.7M(−₩2.3B)	US$2.3M(₩3.1B)	US$415.8K(₩573.7M)

Revenue

FY2023US$64.9M
FY2024US$54.6M
FY2025US$55.9M

Operating profit

FY2023US$1.8M
FY2024US$690.3K
FY2025US$501.2K

Net income

FY2023−US$1.7M
FY2024US$2.3M
FY2025US$415.8K

Key ratios (FY2025)

ROE

0.7%

Debt/Eq

38.0%

Op. margin

0.9%

Net margin

0.7%

Rev. YoY

▲ +2.2%

Why it matters

The company operates a subsidiary, 스타온메디컬 (formerly 서린메디케어), that runs a separate medical aesthetics business alongside the core bio-supply operations.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?